ES2586057T3 - Comprimido de liberación sostenida que comprende pregabalina a través de un sistema de control de la liberación de dos fases - Google Patents
Comprimido de liberación sostenida que comprende pregabalina a través de un sistema de control de la liberación de dos fases Download PDFInfo
- Publication number
- ES2586057T3 ES2586057T3 ES12817601.3T ES12817601T ES2586057T3 ES 2586057 T3 ES2586057 T3 ES 2586057T3 ES 12817601 T ES12817601 T ES 12817601T ES 2586057 T3 ES2586057 T3 ES 2586057T3
- Authority
- ES
- Spain
- Prior art keywords
- phase
- fifty
- release control
- pregabalin
- fifteen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title abstract description 6
- 229960001233 pregabalin Drugs 0.000 title abstract description 6
- 239000007939 sustained release tablet Substances 0.000 title abstract 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract description 8
- 239000004698 Polyethylene Substances 0.000 abstract 1
- -1 polyethylene Polymers 0.000 abstract 1
- 229920000573 polyethylene Polymers 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000008961 swelling Effects 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 238000005188 flotation Methods 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 5
- 229960000913 crospovidone Drugs 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 229940079832 sodium starch glycolate Drugs 0.000 description 4
- 229920003109 sodium starch glycolate Polymers 0.000 description 4
- 239000008109 sodium starch glycolate Substances 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960005291 methylcellulose (100 cps) Drugs 0.000 description 1
- 229940106051 methylcellulose (400 cps) Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un comprimido de liberación sostenida que tiene un sistema de control de la liberación de dos fases, que consiste en una primera fase de control de la liberación que comprende pregabalina o su sal e hidroxipropilmetilcelulosa y una segunda fase de control de la liberación que comprende óxido de polietileno como un polímero de hinchamiento, estando la primera fase de control de la liberación dispersa de forma homogénea en la segunda fase de control de la liberación.
Description
(continuación)
- Componentes
- Ejemplo (mg por un comprimido)
- 1
- 2 3 4 5 6 7 8 9
- Segunda fase de control de la liberación
- Óxido de polietileno (Polyox 301) 100 - 100 100 100 100 50 150 100
- Óxido de polietileno (Polyox 303)
- - 100 - - - - - - -
- Crospovidona
- - - 50 - 50 50 50 50 100
- Almidón glicolato de sodio
- - - - 50 - - - - -
- Dióxido de silicio coloidal
- 15 15 15 15 15 15 15 15 15
- Estearato de magnesio
- 5 5 5 5 5 5 5 5 5
- Total
- 795 795 845 845 795 745 745 845 845
<Tabla 2>
- Componentes
- Ejemplo (mg por un comprimido)
- 10
- 11 12 13 14 15 16 17 18
- Primera fase de control de la liberación
- Pregabalina 300 300 300 300 300 300 300 300 300
- Hidroxipropilmetilcelulosa
- 250 150 150 350 350 100 100 250 250
- Hidroxipropilcelulosa
- 25 15 15 25 25 10 10 15 15
- Segunda fase de control de la liberación
- Óxido de polietileno (Polyox 301) 100 300 200 100 100 100 100 100 100
- Hidroxipropilmetilcelulosa (100.000 cps)
- 100 - - - - - - - -
- Hidroxipropilmetilcelulosa (400 cps)
- - - 100 - - 300 - - -
- Crospovidona
- - 50 50 - - 50 50 - -
- Almidón glicolato de sodio
- - - - 50 - - - 100 200
- Celulosa microcristalina
- - - - 50 100 - - - -
- Dióxido de silicio coloidal
- 15 15 15 15 15 15 15 15 15
- Estearato de magnesio
- 5 5 5 5 5 5 5 5 5
- Total
- 845 835 835 895 895 880 580 785 885
<Tabla 3>
- Componentes
- Ejemplo (mg por un comprimido)
- 19
- 20 21 22
- Primera fase de control de la liberación
- Pregabalina 300 300 300 300
- Hidroxipropilmetilcelulosa
- 150 200 150 150
- Hidroxipropilcelulosa
- 15 20 15 15
6
(continuación)
- Componentes
- Ejemplo (mg por un comprimido)
- 19
- 20 21 22
- Óxido de polietileno (Polyox 301)
- 100 100 100 100
- Hidroxipropilmetilcelulosa(100 cps)
- - - 100 -
- Segunda fase de control de la liberación
- Crospovidona - - - 50
- Dióxido de silicio coloidal
- 15 15 15 15
- Estearato de magnesio
- 5 5 5 5
- Total
- 585 640 685 635
<Tabla 4>
- Componentes
- Ejemplo (mg por un comprimido)
- 23
- 24 25 26 27 28 29 30 31
- Primera fase de control de la liberación
- Pregabalina 150 150 150 150 150 150 150 150 150
- Hidroxipropilmetilcelulosa
- 300 300 450 350 350 500 200 350 400
- Hidroxipropilcelulosa
- 25 25 25 25 25 25 20 20 20
- Segunda fase de control de la liberación
- Óxido de polietileno (Polyox 301) 100 100 100 100 100 100 100 100 100
- Crospovidona
- 50 50 50 - - - - - -
- Almidón glicolato de sodio
- - - - 50 50 50 - - -
- Celulosa microcristalina
- - 150 - 50 200 50 - - -
- Dióxido de silicio coloidal
- 10 10 10 10 10 10 10 10 10
- Estearato de magnesio
- 5 5 5 5 5 5 5 5 5
- Total
- 640 740 790 740 890 890 485 635 685
<Tabla 5>
- Componentes
- Ejemplo (mg por un comprimido)
- 32
- 33 34
- Primera fase de control de la liberación
- Pregabalina 75 75 75
- Hidroxipropilmetilcelulosa
- 300 575 475
- Hidroxipropilcelulosa
- 20 25 15
- Segunda fase de control de la liberación
- Óxido de polietileno (Polyox 301) 100 100 100
- Crospovidona
- 50 50 -
- Almidón glicolato de sodio
- - 50 -
- Celulosa microcristalina
- - - -
- Dióxido de silicio coloidal
- 10 10 10
- Estearato de magnesio
- 5 5 5
- Total
- 560 890 680
7
(continuación)
- Tiempo (h)
- Ejemplo (Tasa de disolución, %)
- 19
- 20 21 22
- 4
- 40,7 39,7 38,7 43,2
- 6
- 54,1 52,8 52,2 56,9
- 8
- 66,1 64,4 63,5 69,1
- 12
- 84,1 80,3 81,5 87,0
- 16
- 95,3 92,3 93,0 98,0
- 24
- 102,8 101,0 103,4 106,5
<Tabla 9>
- Tiempo (h)
- Ejemplo (Tasa de disolución, %)
- 23
- 24 25 26 27 28 29 30 31
- 0,5
- 12,9 12,7 11,5 13,1 12,7 12,3 12,8 12,5 11,0
- 1
- 19,1 19,5 17,7 19,8 18,8 18,6 20,2 19,0 17,4
- 2
- 30,1 29,5 27,2 30,2 28,1 28,0 33,9 29,1 26,7
- 3
- 39,3 36,6 34,0 39,0 35,9 35,5 43,4 37,2 34,4
- 4
- 47,1 43,5 40,8 46,2 42,5 41,6 51,9 44,3 43,2
- 6
- 58,7 50,8 50,2 57,5 53,6 51,1 66,4 56,4 51,7
- 8
- 68,9 58,1 56,6 67,9 63,1 58,7 78,4 66,3 62,0
- 12
- 83,9 70,6 69,7 83,5 77,8 71,6 95,1 81,6 76,0
- 16
- 95,4 80,6 79,8 94,3 87,9 82,1 104,7 92,6 87,4
- 24
- 107,9 95,1 94,8 109,0 101,0 97,0 105,7 104,4 99,1
<Tabla 10>
- Tiempo (h)
- Ejemplo (Tasa de disolución, %)
- 32
- 33 34
- 0,5
- 11,0 10,7 11,6
- 1
- 18,9 16,3 17,8
- 2
- 30,5 24,7 27,6
- 3
- 38,3 31,1 36,7
- 4
- 45,9 36,3 43,2
- 6
- 58,3 44,2 53,4
- 8
- 66,6 51,3 60,5
- 12
- 79,2 63,1 75,4
- 16
- 88,3 73,1 85,3
- 24
- 96,4 86,7 97,1
Ejemplo Experimental 2: Medición de los tiempos de inicio de la flotación y los tiempos de mantenimiento de la flotación
Las pruebas de disolución de los comprimidos preparados en los Ejemplos anteriores se realizaron de acuerdo con la 'Prueba de Disolución 2 (Procedimiento de Pala)' de la Farmacopea Coreana. Como medio de disolución se
10 utilizaron 900 ml de una solución de HCl 0,06 N y la prueba de disolución se realizó a 37 ± 0,5 °C y a la velocidad de rotación de pala de 50 rpm. Se midieron los tiempos de demora de la flotación y después se midieron los tiempos de mantenimiento de la flotación hasta las 24 horas. Los resultados se presentan en las Tablas 11 a 13. Como se muestra en las Tablas 11 a 13, los comprimidos preparados de acuerdo con la presente invención iniciaron la flotación dentro de los 30 minutos y cada flotación se mantuvo durante por lo menos 24 horas.
9
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110074011 | 2011-07-26 | ||
KR20110074011 | 2011-07-26 | ||
PCT/KR2012/005831 WO2013015578A1 (en) | 2011-07-26 | 2012-07-20 | Sustained release tablet comprising pregabalin through two-phase release-controlling system |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2586057T3 true ES2586057T3 (es) | 2016-10-11 |
Family
ID=47601326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12817601.3T Active ES2586057T3 (es) | 2011-07-26 | 2012-07-20 | Comprimido de liberación sostenida que comprende pregabalina a través de un sistema de control de la liberación de dos fases |
Country Status (7)
Country | Link |
---|---|
US (1) | US20140161880A1 (es) |
EP (1) | EP2736499B1 (es) |
JP (1) | JP6170918B2 (es) |
KR (1) | KR101724024B1 (es) |
CN (1) | CN103702664B (es) |
ES (1) | ES2586057T3 (es) |
WO (1) | WO2013015578A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2415460A1 (de) * | 2010-08-03 | 2012-02-08 | ratiopharm GmbH | Orale Darreichungsform von Pregabalin |
KR102221846B1 (ko) * | 2014-04-07 | 2021-02-26 | 영진약품 주식회사 | 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법 |
CN105979936A (zh) | 2014-10-24 | 2016-09-28 | 江苏恒瑞医药股份有限公司 | 一种普瑞巴林缓释制剂 |
CN104906064B (zh) * | 2015-05-15 | 2017-12-22 | 中国药科大学 | 一种普瑞巴林胃漂浮缓释片剂及其制备方法 |
CN104840443B (zh) * | 2015-05-27 | 2018-04-27 | 齐鲁制药有限公司 | 含活性成分普瑞巴林的药物组合物 |
BR112019000636A2 (pt) * | 2016-07-17 | 2019-04-30 | Mapi Pharma Ltd. | formas de dosagem de liberação prolongada de pregabalina |
JP6919119B2 (ja) * | 2017-01-23 | 2021-08-18 | 日新製薬株式会社 | 3位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。 |
KR102039345B1 (ko) * | 2017-02-01 | 2019-11-01 | 지엘팜텍주식회사 | 프레가발린 함유 고팽윤성 서방성 삼중정제 |
KR102039344B1 (ko) * | 2017-02-01 | 2019-11-01 | 지엘팜텍주식회사 | 프레가발린 함유 경구용 서방성 삼중정제 |
TW202002958A (zh) | 2018-03-22 | 2020-01-16 | 日商日東電工股份有限公司 | 含普瑞巴林(pregabalin)之組成物的製造方法及含普瑞巴林之組成物 |
WO2019238068A1 (zh) * | 2018-06-13 | 2019-12-19 | 北京泰德制药股份有限公司 | 一种普瑞巴林缓释组合物及其制备方法 |
JP2021529158A (ja) * | 2018-06-19 | 2021-10-28 | ナショナル ユニバーシティー オブ シンガポールNational University of Singapore | 様々な適応症についての生物学的利用能を向上させるための5−ヒドロキシトリプトファンの製剤 |
CN109044981B (zh) * | 2018-08-07 | 2021-02-19 | 广州帝奇医药技术有限公司 | 一种普瑞巴林胃漂浮型缓释片及其制备方法 |
KR20220048341A (ko) * | 2020-10-12 | 2022-04-19 | 뉴지랩테라퓨틱스 주식회사 | 나파모스타트 또는 이의 약제학적으로 허용가능한 염을 함유하는 방출 조절 제형 및 이의 제조방법 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5945125A (en) * | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
US6337091B1 (en) * | 1997-10-27 | 2002-01-08 | Temple University - Of The Commonwealth System Of Higher Education | Matrix for controlled delivery of highly soluble pharmaceutical agents |
BR9908911A (pt) * | 1998-03-19 | 2001-10-02 | Bristol Myers Squibb Co | Sistema bifásico e processo de distribuição por liberação controlada de substâncias farmacêuticas de alta solubilidade |
US6723340B2 (en) * | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
US20070184104A1 (en) * | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
JP2005132803A (ja) * | 2003-10-31 | 2005-05-26 | Ono Pharmaceut Co Ltd | 胃内滞留固形剤 |
US20070196396A1 (en) * | 2004-02-11 | 2007-08-23 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
NL2000281C2 (nl) * | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
KR100791844B1 (ko) * | 2006-06-30 | 2008-01-07 | 주식회사유한양행 | 메트포르민 또는 그의 염을 함유하는 서방성 제제 및 그의제조방법 |
US20090011018A1 (en) * | 2006-12-28 | 2009-01-08 | Astellas Pharma Inc., | Sustained release formulation for tacrolimus |
JP2008169173A (ja) * | 2007-01-15 | 2008-07-24 | Kissei Pharmaceut Co Ltd | 炭水化物分解酵素阻害剤の胃内滞留型徐放性製剤 |
WO2009066325A1 (en) * | 2007-11-23 | 2009-05-28 | Lupin Limited | Controlled release pharmaceutical compositions of pregabalin |
CN102548544B (zh) * | 2009-10-09 | 2015-01-21 | 永进药品工业株式会社 | 同时具有速效特性和长效特性的药物组合物 |
KR101317592B1 (ko) * | 2009-10-28 | 2013-10-15 | 씨제이제일제당 (주) | 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제 |
KR101648490B1 (ko) * | 2009-11-02 | 2016-08-17 | 한미사이언스 주식회사 | 위체류 약물 전달시스템을 이용한 서방성 경구용 제제 |
-
2012
- 2012-07-20 EP EP12817601.3A patent/EP2736499B1/en active Active
- 2012-07-20 KR KR1020120079177A patent/KR101724024B1/ko not_active Application Discontinuation
- 2012-07-20 CN CN201280036427.6A patent/CN103702664B/zh active Active
- 2012-07-20 ES ES12817601.3T patent/ES2586057T3/es active Active
- 2012-07-20 WO PCT/KR2012/005831 patent/WO2013015578A1/en active Application Filing
- 2012-07-20 JP JP2014522743A patent/JP6170918B2/ja active Active
- 2012-07-20 US US14/234,219 patent/US20140161880A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20130012923A (ko) | 2013-02-05 |
WO2013015578A1 (en) | 2013-01-31 |
KR101724024B1 (ko) | 2017-04-06 |
CN103702664B (zh) | 2016-10-19 |
JP6170918B2 (ja) | 2017-07-26 |
EP2736499A1 (en) | 2014-06-04 |
JP2014521639A (ja) | 2014-08-28 |
CN103702664A (zh) | 2014-04-02 |
EP2736499B1 (en) | 2016-05-11 |
US20140161880A1 (en) | 2014-06-12 |
EP2736499A4 (en) | 2015-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2586057T3 (es) | Comprimido de liberación sostenida que comprende pregabalina a través de un sistema de control de la liberación de dos fases | |
CY1120852T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας | |
JP2014218522A5 (es) | ||
BR112012007412A2 (pt) | tabletes transformáveis de forma oral. | |
HRP20100038T1 (hr) | Farmaceutski vaginalni gel koji sadrži tenofovir | |
WO2009066315A3 (en) | Sustained release compositions of trimetazidine and process for preparation thereof | |
CO6290635A2 (es) | Composición farmaceútica que comprende una forma de dosis unitaria sólida de uno o más ingredientes activos y un polímero insoluble en agua y/o un polímero soluble en agua | |
UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
AR080491A1 (es) | Formulaciones orales y sales lipofilicas de metilnaltrexona | |
EA201071204A1 (ru) | Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности | |
BRPI0908942A2 (pt) | Sistemas de distribuição de fármacos compreendendo fármacos fracamente básicos e ácidos orgânicos | |
EA201490653A1 (ru) | Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств | |
AR063138A1 (es) | Comprimidos pediatricos de capecitabina | |
CO6470841A2 (es) | Preparación de sólido que presenta propiedad de disolución mejorada de un medicamento a partir de la misma | |
JP2018527305A5 (es) | ||
AR094936A1 (es) | Suspensión para administración oral que comprende tolvaptán amorfo, y a un método para producirla | |
AR074739A1 (es) | Comprimidos de capecitabina de disgregacion rapida | |
CY1118036T1 (el) | Βελτιστοποιημενη συνθεση καθαρων μη-πολυμορφικων, κρυσταλλικων χολικων οξεων με καθορισμενο μεγεθος σωματιδιων | |
JP2016108327A5 (es) | ||
RU2013139558A (ru) | Фармацевтическая композиция, содержащая лекарственное средство, имеющее слабую растворимость в воде | |
TR201001417A1 (tr) | Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu | |
WO2010046932A3 (en) | Extended release pharmaceutical composition of minocycline and process thereof | |
JP2008539169A5 (es) | ||
MX2013001637A (es) | Composiciones farmaceuticas de liberacion controlada oral de blonanserina. | |
WO2011083402A3 (en) | Immediate release compositions of acid labile drugs |